Multiple studies have identified TP53 mutations and 17p deletions as independent drivers of resistance to chemotherapeutic agents in CLL (Döhner et al., 1995; Hallek et al., 2010). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.